Fulton Bank’s NovoCure NVCR Stock Holding History

Fulton Bank’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,193	Closed	-$264K	–	537
2021 Q2	$264K	Buy	+1,193	New	+$232K	0.01%	429

Other funds holding NVCR

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fulton Bank's NVCR Position: Q3 2021 in Review

Fulton Bank sold out of NovoCure (NVCR) in Q3 2021, closing a stake of 1,193 shares — an estimated $264K sold.

Fulton Bank first reported a position in NVCR in Q2 2021 and held it in 1 quarter. The position peaked at $264K in Q2 2021. 317 funds tracked by Wall St. Rank hold NVCR as of Q3 2021.

Fulton Bank reported no remaining NovoCure position as of Q3 2021 after selling out during the quarter.
Fulton Bank sold 1,193 NovoCure shares in Q3 2021, an estimated $264K.
Fulton Bank first reported a position in NovoCure in Q2 2021 and held it in 1 quarter.
Fulton Bank's NovoCure position peaked at $264K in Q2 2021.
317 funds tracked by Wall St. Rank held NovoCure as of Q3 2021.

Based on Fulton Bank's 13F filing for Q3 2021, filed 5 Oct 2021.